Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology

Core Viewpoint - Trinity Biotech plc has secured an additional $4 million in debt financing to support its continuous glucose monitoring technology and transformation plan aimed at increasing profitability and cash flow generation [1][2][3] Group 1: Financing and Development - The company has obtained$4 million in debt financing from Perceptive Advisors, its primary lender [1] - The additional liquidity will aid in the development of Trinity Biotech's continuous glucose monitoring (CGM) technology [2] - The company is focusing its growth efforts on CGM technology, especially following positive results from its recent pre-pivotal trial [2] Group 2: Transformation Plan - Trinity Biotech's comprehensive transformation plan aims to enhance profitability and cash flow across its portfolio of operating businesses [3] - Steps have been taken to increase operational efficiencies to strengthen the company's financial position [3] - The company will continue to optimize its business portfolio and capital structure as part of the transformation plan [3] Group 3: Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors [6] - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments [6] - Recently, Trinity Biotech entered the wearable biosensor industry through the acquisition of Waveform Technologies Inc.'s biosensor assets [6]